Early unrecognised SARS-CoV-2 introductions shaped the first pandemic wave, Sweden, 2020.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
Oct 2024
Historique:
medline: 11 10 2024
pubmed: 11 10 2024
entrez: 11 10 2024
Statut: ppublish

Résumé

BackgroundDespite the unprecedented measures implemented globally in early 2020 to prevent the spread of SARS-CoV-2, Sweden, as many other countries, experienced a severe first wave during the COVID-19 pandemic.AimWe investigated the introduction and spread of SARS-CoV-2 into Sweden.MethodsWe analysed stored respiratory specimens (n = 1,979), sampled 7 February-2 April 2020, by PCR for SARS-CoV-2 and sequenced PCR-positive specimens. Sequences generated from newly detected cases and stored positive specimens February-June 2020 (n = 954) were combined with sequences (Sweden: n = 730; other countries: n = 129,913) retrieved from other sources for Nextstrain clade assignment and phylogenetic analyses.ResultsTwelve previously unrecognised SARS-CoV-2 cases were identified: the earliest was sampled on 3 March, 1 week before recognised community transmission. We showed an early influx of clades 20A and 20B from Italy (201/328, 61% of cases exposed abroad) and clades 19A and 20C from Austria (61/328, 19%). Clade 20C dominated the first wave (20C: 908/1,684, 54%; 20B: 438/1,684, 26%; 20A: 263/1,684, 16%), and 800 of 1,684 (48%) Swedish sequences formed a country-specific 20C cluster defined by a spike mutation (G24368T). At the regional level, the proportion of clade 20C sequences correlated with an earlier weighted mean date of COVID-19 deaths.ConclusionCommunity transmission in Sweden started when mitigation efforts still focused on preventing influx. This created a transmission advantage for clade 20C, likely introduced from ongoing cryptic spread in Austria. Therefore, pandemic preparedness should have a comprehensive approach, including capacity for large-scale diagnostics to allow early detection of travel-related cases and community transmission.

Identifiants

pubmed: 39392000
doi: 10.2807/1560-7917.ES.2024.29.41.2400021
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Robert Dyrdak (R)

Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Emma B Hodcroft (EB)

Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Swiss Institute of Bioinformatics, Lausanne, Switzerland.

Sandra Broddesson (S)

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Malin Grabbe (M)

Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Hildur Franklin (H)

Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, Örebro, Sweden.

Magnus Gisslén (M)

Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.
Public Health Agency of Sweden, Solna, Sweden.

Maricris E Holm (ME)

Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Magnus Lindh (M)

Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Joanna Nederby-Öhd (J)

Department of Infectious Disease Prevention and Control, Stockholm Region, Stockholm, Sweden.
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Johan Ringlander (J)

Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Martin Sundqvist (M)

Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, Örebro, Sweden.

Richard A Neher (RA)

Biozentrum, University of Basel, Basel, Switzerland.
Swiss Institute of Bioinformatics, Lausanne, Switzerland.

Jan Albert (J)

Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH